Pyxis Oncology (PYXS) Non-Current Assets (2020 - 2026)
Pyxis Oncology (PYXS) posted quarterly Non-Current Assets of $19.4 million for Q4 2025, down 21.53% year-over-year from $24.7 million in Q4 2024, and down 13.83% quarter-over-quarter from $22.5 million in Q3 2025.
Pyxis Oncology (PYXS) Non-Current Assets (2020 - 2026) Analysis & Trends
Pyxis Oncology (PYXS) has reported Non-Current Assets for 6 consecutive years, with $19.4 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Non-Current Assets fell 21.53% year-over-year to $19.4 million; the TTM figure through Dec 2025 stood at $89.2 million (down 46.39% YoY), while the FY2025 annual figure was $19.4 million, down 21.53% from the prior year.
- Non-Current Assets retreated to $19.4 million in Q4 2025 per PYXS's latest filing, from $22.5 million in the prior quarter.
- Across five years, Non-Current Assets topped out at $49.1 million in Q4 2023 and bottomed at $1.3 million in Q4 2021.
- Historically, Non-Current Assets has averaged $26.4 million across 5 years, with a median of $24.4 million in 2024.
- Annual changes were most pronounced in 2023 — Non-Current Assets soared 1743.56% — and 2025, when it plunged 51.49%.
- Pyxis Oncology's Non-Current Assets stood at $1.3 million in 2021, then surged by 1737.31% to $24.8 million in 2022, then soared by 98.34% to $49.1 million in 2023, then sank by 49.63% to $24.7 million in 2024, then slipped by 21.53% to $19.4 million in 2025.
- Business Quant data shows PYXS's Non-Current Assets at $19.4 million in Q4 2025, $22.5 million in Q3 2025, and $23.3 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 5.15 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.96 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 938.60 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 468.65 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 18.06 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 6.80 Bn |
| 10 | Pyxis Oncology | 199.01 Mn | 166.02 Mn | - | 18.19 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 18.19 Mn |
| Dec 31, 2025 | 19.42 Mn |
| Sep 30, 2025 | 22.53 Mn |
| Jun 30, 2025 | 23.26 Mn |
| Mar 31, 2025 | 24.00 Mn |
| Dec 31, 2024 | 24.74 Mn |
| Sep 30, 2024 | 46.44 Mn |
| Jun 30, 2024 | 47.35 Mn |
| Mar 31, 2024 | 47.84 Mn |
| Dec 31, 2023 | 49.12 Mn |
| Sep 30, 2023 | 47.60 Mn |
| Jun 30, 2023 | 25.93 Mn |
| Mar 31, 2023 | 26.62 Mn |
| Dec 31, 2022 | 24.77 Mn |
| Sep 30, 2022 | 21.09 Mn |
| Jun 30, 2022 | 15.97 Mn |
| Mar 31, 2022 | 1.44 Mn |
| Dec 31, 2021 | 1.35 Mn |
| Sep 30, 2021 | 5.15 Mn |
| Dec 31, 2020 | 2.05 Mn |